Cargando…
CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib
Gastrointestinal stromal tumor (GIST) is the most major mesenchymal neoplasm of the digestive tract. Up to now, imatinib mesylate has been used as a standard first-line treatment for irresectable and metastasized GIST patients or adjuvant treatment for advanced GIST patients who received surgical re...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978997/ https://www.ncbi.nlm.nih.gov/pubmed/27506146 http://dx.doi.org/10.1038/srep31071 |
_version_ | 1782447253483421696 |
---|---|
author | Tian, Guang-Ang Zhu, Chun-Chao Zhang, Xiao-Xin Zhu, Lei Yang, Xiao-Mei Jiang, Shu-Heng Li, Rong-Kun Tu, Lin Wang, Yang Zhuang, Chun He, Ping Li, Qing Cao, Xiao-Yan Cao, Hui Zhang, Zhi-Gang |
author_facet | Tian, Guang-Ang Zhu, Chun-Chao Zhang, Xiao-Xin Zhu, Lei Yang, Xiao-Mei Jiang, Shu-Heng Li, Rong-Kun Tu, Lin Wang, Yang Zhuang, Chun He, Ping Li, Qing Cao, Xiao-Yan Cao, Hui Zhang, Zhi-Gang |
author_sort | Tian, Guang-Ang |
collection | PubMed |
description | Gastrointestinal stromal tumor (GIST) is the most major mesenchymal neoplasm of the digestive tract. Up to now, imatinib mesylate has been used as a standard first-line treatment for irresectable and metastasized GIST patients or adjuvant treatment for advanced GIST patients who received surgical resection. However, secondary resistance to imatinib usually happens, resulting in a major obstacle in GIST successful therapy. In this study, we first found that collagen and calcium binding EGF domains 1 (CCBE1) expression gradually elevated along with the risk degree of NIH classification, and poor prognosis emerged in the CCBE1-positive patients. In vitro experiments showed that recombinant CCBE1 protein can enhance angiogenesis and neutralize partial effect of imatinib on the GIST-T1 cells. In conclusion, these data indicated that CCBE1 may be served as a new predictor of prognosis in post-operative GIST patients and may play an important role in stimulating GIST progression. |
format | Online Article Text |
id | pubmed-4978997 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49789972016-08-18 CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib Tian, Guang-Ang Zhu, Chun-Chao Zhang, Xiao-Xin Zhu, Lei Yang, Xiao-Mei Jiang, Shu-Heng Li, Rong-Kun Tu, Lin Wang, Yang Zhuang, Chun He, Ping Li, Qing Cao, Xiao-Yan Cao, Hui Zhang, Zhi-Gang Sci Rep Article Gastrointestinal stromal tumor (GIST) is the most major mesenchymal neoplasm of the digestive tract. Up to now, imatinib mesylate has been used as a standard first-line treatment for irresectable and metastasized GIST patients or adjuvant treatment for advanced GIST patients who received surgical resection. However, secondary resistance to imatinib usually happens, resulting in a major obstacle in GIST successful therapy. In this study, we first found that collagen and calcium binding EGF domains 1 (CCBE1) expression gradually elevated along with the risk degree of NIH classification, and poor prognosis emerged in the CCBE1-positive patients. In vitro experiments showed that recombinant CCBE1 protein can enhance angiogenesis and neutralize partial effect of imatinib on the GIST-T1 cells. In conclusion, these data indicated that CCBE1 may be served as a new predictor of prognosis in post-operative GIST patients and may play an important role in stimulating GIST progression. Nature Publishing Group 2016-08-10 /pmc/articles/PMC4978997/ /pubmed/27506146 http://dx.doi.org/10.1038/srep31071 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Tian, Guang-Ang Zhu, Chun-Chao Zhang, Xiao-Xin Zhu, Lei Yang, Xiao-Mei Jiang, Shu-Heng Li, Rong-Kun Tu, Lin Wang, Yang Zhuang, Chun He, Ping Li, Qing Cao, Xiao-Yan Cao, Hui Zhang, Zhi-Gang CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib |
title | CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib |
title_full | CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib |
title_fullStr | CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib |
title_full_unstemmed | CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib |
title_short | CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib |
title_sort | ccbe1 promotes gist development through enhancing angiogenesis and mediating resistance to imatinib |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4978997/ https://www.ncbi.nlm.nih.gov/pubmed/27506146 http://dx.doi.org/10.1038/srep31071 |
work_keys_str_mv | AT tianguangang ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT zhuchunchao ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT zhangxiaoxin ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT zhulei ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT yangxiaomei ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT jiangshuheng ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT lirongkun ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT tulin ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT wangyang ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT zhuangchun ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT heping ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT liqing ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT caoxiaoyan ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT caohui ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib AT zhangzhigang ccbe1promotesgistdevelopmentthroughenhancingangiogenesisandmediatingresistancetoimatinib |